![Adeno-associated virus](https://technewslit.com/sciencebusiness/wp-content/uploads/2019/11/AdenoAssociatedVirus_BerkeleyLab-150x100.jpg)
A developer of synthetic antibodies for neurodegenerative disorders delivered like gene therapies is raising €129 million ($US 138 million) in its first venture funding round. . . . → Read More: Antibody/Gene Therapy Biotech Gains $138 Million in Early Funds